The Goldman Sachs Group Issues Positive Forecast for TG Therapeutics (NASDAQ:TGTX) Stock Price

TG Therapeutics (NASDAQ:TGTX) had its price target upped by The Goldman Sachs Group from $20.00 to $22.00 in a research report report published on Tuesday, Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the biopharmaceutical company’s stock.

A number of other brokerages have also issued reports on TGTX. HC Wainwright reiterated a “buy” rating and set a $49.00 price target on shares of TG Therapeutics in a research report on Wednesday, September 18th. B. Riley upped their price objective on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, TD Cowen assumed coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $50.00 target price on the stock. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, TG Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.67.

TG Therapeutics Stock Up 6.2 %

TG Therapeutics stock opened at $25.86 on Tuesday. The firm has a market capitalization of $4.00 billion, a P/E ratio of -258.00 and a beta of 2.19. The company has a 50-day simple moving average of $23.51 and a 200-day simple moving average of $20.17. TG Therapeutics has a one year low of $9.81 and a one year high of $26.99. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.83 and a current ratio of 3.58.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). The firm had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. TG Therapeutics’s revenue for the quarter was down 49.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.73 EPS. As a group, equities analysts expect that TG Therapeutics will post 0.13 earnings per share for the current year.

Institutional Investors Weigh In On TG Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Marshall Wace LLP bought a new position in shares of TG Therapeutics during the 2nd quarter valued at about $36,501,000. Hood River Capital Management LLC bought a new stake in TG Therapeutics during the first quarter worth approximately $22,420,000. Principal Financial Group Inc. boosted its holdings in TG Therapeutics by 1,549.4% during the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock worth $18,061,000 after buying an additional 725,371 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of TG Therapeutics in the second quarter valued at $10,423,000. Finally, Assenagon Asset Management S.A. acquired a new stake in shares of TG Therapeutics during the 2nd quarter valued at $8,698,000. 58.58% of the stock is currently owned by institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.